Over recent decades, targeted therapies have transformed the management of moderate-to-severe AD, particularly with the introduction of dupilumab, a monoclonal antibody against IL-4 receptor alpha, the shared receptor subunit for IL-4 and IL-13. Here, IL4 is linked to Alzheimer disease.